

**COVID-19 PCR Test** 

PATIENT/CLIENT

**DOB:** 1995-06-30

**Age:** 26

Bernardo Aceituno Cabezas

ID: 913986951

Location: MIT Medical (HUCL)

ORDERING PROVIDER SPECIMEN Report date: Jan 05, 2021

MIT Medical Type: Anterior Nares (dry)
25 Carleton Street Barcode: D-6615131304
Building E23 Date Collected: Jan 05, 2021
Cambridge, MA 02142 Time Collected: 02:18 pm EST
NPI: 1962476994 Received: Jan 05, 2021

## **NEGATIVE for SARS-CoV-2**

- Variability in collection technique can reduce the sensitivity of the test, and SARS-CoV-2 may not be detected in early stages of infection.
- False negatives are possible.
- If this patient is experiencing symptoms, consider collecting a new sample for COVID-19 testing or testing for other respiratory viruses.
- Collection of multiple specimens may be necessary to detect the SARS-CoV-2 virus.

DETAILS	Test	PCR Results
	SARS-CoV-2 amplification test	NEGATIVE
	To learn more about the technical details of this test, please see the test methodology and limitations section.	

## HELPFUL INFORMATION FOR THE PATIENT

If you have symptoms of illness (such as fever, cough, and/or shortness of breath), you should discuss your symptoms and your test results with your doctor, who can decide how to care for you.

The US Centers for Disease Control and Prevention (CDC) has provided useful information on how to care for yourself at home and how others in your household may protect themselves. The CDC has also provided information on when to seek medical attention. Key points are outlined below for your reference, and you can find more information at: <a href="https://www.cdc.gov/coronavirus/2019-ncov">https://www.cdc.gov/coronavirus/2019-ncov</a>.

The CDC recommends that individuals experiencing the following symptoms get medical attention immediately:

- Trouble breathing
- Persistent pain or pressure in the chest
- New confusion
- Inability to stay awake or wake after sleeping
- Bluish lips or face

If you are a healthcare professional, first responder, or frontline worker with questions about returning to work, consider contacting your place of employment or local health department in regards to discontinuation of self-isolation, as they may differ from the CDC's guidelines.

**CDC: FOR PEOPLE** 

• The CDC recommends that if you are or might be sick with COVID-19 stay home except to get medical care, and avoid using public transportation if you must leave your home. Even if you have no symptoms,

## **WHO ARE SICK**

you can pass the infection on to others.

- Separate yourself from other people in your home as much as possible.
- Wear a facemask over your nose and mouth if you are around other people, even at home.
- Cover your coughs and sneezes with a tissue. Dispose of the tissue in a lined trash can. Clean your hands often with soap and water for at least 20 seconds, and avoid sharing household items (for example, utensils, towels, glasses) as much as possible.
- Clean and disinfect all frequently touched surfaces in your home often. If you are able, clean your bathroom and bedroom yourself and let others clean common areas.
- Please work with your provider to determine appropriate next steps, including when to end self-isolation.
- Learn more at https://www.cdc.gov/coronavirus/2019-ncov.

## TEST METHODOLOGY AND LIMITATIONS

The technical component of this test was based on the reverse-transcriptase PCR (RT-PCR) technique for the detection of SARS-CoV-2 and it was performed by Harvard University Clinical Laboratory, 52 Oxford Street, Cambridge, MA 02138, CLIA #22D2209289, CAP PT #898263701.

To learn more about the technical details of this test, visit <a href="https://color.com/covid19-details">https://color.com/covid19-details</a>.

This test has been authorized by the FDA under an Emergency Use Authorization (EUA) for use by Harvard University Clinical Laboratory, but is not FDA cleared or approved. This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Cambridge
MIT Medical
Building E23
25 Carleton Street
Cambridge, MA 02142

Lexington MIT Lincoln Laboratory Annex V 244 Wood Street Lexington, MA 02421

Urgent Care
MIT Medical
Building E23
25 Carleton Street
Cambridge, MA 02142

Medical Director: Cecilia Stuopis, MD